Moderna May Crush Competitors

Moderna is more than just the coronavirus vaccine. Besides being the vaccine leader, the company also aims to take over the market to prevent other respiratory diseases, specifically the flu.

Currently, the flu vaccine market is full of competition. Recently, the FDA made available nine flu vaccines made by six different companies.

The goal of Moderna is to stand out from the competition, and it is confident in itself because of a significant advantage in regards to how it deals with the flu.

Let’s get a closer look.

Tackling The Flu

Moderna wants to use the same technology used in the coronavirus vaccine. The company uses messenger RNA, which orders the body to produce the proteins related to the virus, so the body learns to mount an immune response against the virus.

The production of mRNA technology is faster than producing proteins or weakened pathogens (usual steps in traditional vaccine production). So, in terms of time, mRNA vaccines are better.

A good example is that it only took two months to bring an omicron-specific vaccine to human trials.

Usually, vaccines take over six months to produce. If the Moderna vaccine succeeds in the trials, it will be way ahead of the market.

A Way to Stand Out

The company’s primary goal is to customize vaccines according to the needs of every country.

Imagine having customized and produced vaccines in a really short period of time. Also, the ordering and delivery will be an easy process.

What’s Happening Now?

Moderna is just one phase away from beginning clinical testing. If these products are successful, imagine the products that will come out to the market in the next couple of years.

Be sure that while the market is crowded, Moderna is standing out, and it will surely be the market leader in respiratory vaccines.